Considering the prevalence of germline AIP mutations in young patients with apparently sporadic pituitary tumors, while no formal guidelines exist, several groups recommend that screening for AIP mutations be performed in all patients diagnosed before 18 years of age and in patients harboring a macroadenoma diagnosed before 30 years of age [24, 40, 44]. The gene discussed is AIP; the disease is pituitary tumor.